Personalis reported record revenues of $19.5 million for the second quarter of 2020, a 23% increase compared to $15.8 million in the same period of the prior year. The VA MVP accounted for $14.8 million of total revenues, while biopharmaceutical and other customers contributed $4.7 million.
Reported record revenues of $19.5 million, a 23% increase year-over-year.
32 customers have placed orders for NeXT as of June 30, 2020, with 6 new customers in Q2 2020.
Announced collaborations with Sarepta Therapeutics and Berry Genomics.
Completed the 75,000th whole human genome sequenced under the VA MVP contract.
Due to continued uncertainty surrounding the COVID-19 pandemic, Personalis will not provide an outlook for fiscal 2020 at this time and will plan to give an update during its third quarter earnings announcement and press release, to the extent practicable, based on available information at that time.
Analyze how earnings announcements historically affect stock price performance